Which of the following statements concerning traveler's diarrhea (TD) is true?
Rationale:
Traveler's diarrhea can usually be avoided by not eating raw vegetables, seafood, or eggs when traveling to third-world countries. This advice is rooted in the fact that contaminated food and water are primary sources of TD pathogens. Avoiding risky foods reduces exposure to bacteria, viruses, and parasites commonly found in undercooked or raw items in areas with poor sanitation.
B: Taking one dose of antibiotic one day before a trip does not provide effective protection against TD, as prophylactic antibiotic use requires specific regimens and is generally not recommended due to resistance risks.
C: Helicobacter pylori is primarily linked to gastric ulcers, not traveler's diarrhea, which is mostly caused by enteric bacteria like E. coli, making this option factually inaccurate.
D: Phillip’s Milk of Magnesia is an antacid and laxative, not an agent for preventing or treating TD, therefore it lacks efficacy against the infectious causes of traveler’s diarrhea.
Ondansetron blocks emetogenic impulses at the following site(s).
Rationale:
Ondansetron blocks emetogenic impulses at all of the following sites: vagal afferents in intestines, nucleus tractus solitarius, and chemoreceptor trigger zone. This broad action contributes to its effectiveness in preventing nausea and vomiting by inhibiting serotonin receptors in multiple critical areas involved in the emetic reflex pathway, thereby reducing signaling that triggers the vomiting center.
A: Vagal afferents in intestines Ondansetron targets vagal afferents but also affects other central sites; focusing solely on intestinal vagal afferents omits its central actions critical for comprehensive antiemetic effects.
B: Nucleus tractus solitarius While ondansetron acts here, limiting its site to the nucleus tractus solitarius ignores peripheral actions on vagal afferents and the chemoreceptor trigger zone essential for full efficacy.
C: Chemoreceptor trigger zone Although the chemoreceptor trigger zone is a key target, ondansetron's blockade extends beyond this area, including peripheral and central sites, making this option incomplete and too narrow.
Omeprazole:
Rationale:
Omeprazole is an irreversible inhibitor of the hydrogen/potassium adenosine triphosphatase locus of the gastric parietal cell. This mechanism allows it to effectively block the final step in gastric acid secretion by covalently binding to the proton pump, leading to prolonged acid suppression. Its irreversible nature distinguishes it from reversible inhibitors and underpins its potent efficacy in acid-related disorders.
B: Reducing gastric acid secretion is a result of omeprazole’s inhibition but not its defining characteristic; the core action specifically involves irreversible proton pump blockade rather than a general reduction in acid.
C: Although useful in Zollinger-Ellison syndrome, omeprazole is not uniquely chosen solely for this indication; other proton pump inhibitors may also be appropriate.
D: Omeprazole’s plasma half-life is brief, approximately one hour, but this does not fully explain its prolonged acid suppression due to irreversible enzyme binding.
Sucralfate promotes healing of duodenal ulcer by
Rationale:
Sucralfate promotes healing of duodenal ulcer by coating the ulcer and preventing the action of acid-pepsin on ulcer base.
This medication forms a protective barrier over the ulcer site, shielding it from corrosive gastric acid and pepsin enzymes, thereby allowing tissue repair. Unlike other agents, it does not significantly enhance mucus or bicarbonate secretion but acts primarily through physical protection, facilitating an environment conducive to healing without altering gastric secretions.
A: Enhancing gastric mucus and bicarbonate secretion describes other treatments; sucralfate mainly acts by forming a protective barrier rather than increasing these secretions.
C: Promoting regeneration of mucosa implies a direct stimulatory effect on tissue growth, which sucralfate does not possess; it mainly protects rather than regenerates.
D: Both (a) and (b) combines mucus secretion enhancement with coating action, but sucralfate primarily works only by coating and protecting the ulcer base, not by increasing secretions.
For each effect, select the agent that is most likely associated with it: Can be alternated with an antacid mixture to control diarrhea
Rationale:
Aluminum hydroxide can be alternated with an antacid mixture to control diarrhea. Aluminum hydroxide has constipating effects, making it suitable to balance diarrhea when used alongside antacids. Its ability to neutralize stomach acid while reducing bowel motility helps manage diarrhea effectively. This dual action makes it the preferred agent in this context over others with different side effects.
A: Sodium bicarbonate primarily neutralizes acid quickly but lacks constipating properties, so it cannot effectively control diarrhea when alternated with antacids. Its rapid action differs from the needed prolonged effect.
C: Calcium carbonate mainly causes belching and can induce constipation, but it is not typically alternated for controlling diarrhea due to its potential to cause rebound acid secretion.
D: Magnesium hydroxide often induces diarrhea due to its osmotic laxative properties, making it unsuitable for controlling diarrhea when combined with antacid mixtures.
The most effective antimotion sickness drug suitable for short brisk journeys is
Rationale:
Hyoscine is the most effective antimotion sickness drug suitable for short brisk journeys. Hyoscine acts rapidly on the vestibular system, effectively preventing nausea and vomiting during brief travel. Its fast onset and strong anticholinergic properties make it ideal for quick relief in short trips, unlike other drugs that may require longer periods or have delayed action.
A: Promethazine theoclate has a slower onset and sedative effects, making it less suitable for short, brisk journeys where rapid action is necessary to prevent motion sickness symptoms effectively.
B: Cinnarizine primarily targets calcium channels and is more suited for prolonged motion sickness prevention, lacking the quick efficacy required for short, rapid travel scenarios.
C: Prochlorperazine mainly treats severe nausea and vomiting but has a slower onset and is usually used in clinical settings, not ideal for immediate relief during brief travel.
Which of the following is most effective in the treatment of peptic ulcer disease?
Rationale:
Cimetidine is most effective in the treatment of peptic ulcer disease. Cimetidine is an H2 receptor antagonist that reduces gastric acid secretion, promoting ulcer healing and symptom relief. Its targeted mechanism specifically addresses acid-related mucosal damage, making it a primary therapeutic agent in managing peptic ulcers compared to other drug classes with unrelated pharmacological actions.
A: Bromocriptine is a dopamine agonist primarily used for Parkinson’s disease and hyperprolactinemia, lacking any significant role in reducing gastric acid or healing peptic ulcers.
C: Ergotamine acts as a vasoconstrictor used for migraine relief, without any influence on gastric acid secretion or mucosal protection in peptic ulcer disease.
D: Ketanserin functions as a serotonin receptor antagonist affecting vascular tone, with no direct effect on gastric acid levels or ulcer healing mechanisms.
Ranitidine differs from cimetidine in the following manner.
Rationale:
Ranitidine does not have antiandrogenic action.
Ranitidine lacks the antiandrogenic effects seen with cimetidine, which can cause hormonal side effects such as gynecomastia. This difference arises because ranitidine selectively blocks H2 receptors without interfering with androgen receptors, making it preferable when avoiding endocrine disturbances related to cimetidine’s hormonal interactions.
A: It is less potent Ranitidine generally exhibits equal or greater potency compared to cimetidine in reducing gastric acid secretion, so the claim of lower potency does not align with pharmacological data.
B: It is shorter acting Ranitidine typically has a longer duration of action than cimetidine, providing more sustained acid suppression. Therefore, describing it as shorter acting misrepresents its pharmacokinetic profile.
D: It produces more CNS side effects Cimetidine is more commonly associated with central nervous system adverse effects, including confusion and dizziness, whereas ranitidine tends to have a lower incidence of such neurological side effects.
Sulfasalazine:
Rationale:
Sulfasalazine is used for maintenance treatment of ulcerative colitis. This medication reduces inflammation and helps sustain remission in patients with ulcerative colitis by modulating immune responses in the colon. Its efficacy in maintaining long-term disease control makes it a preferred option for ongoing management of this specific inflammatory bowel condition, distinguishing it from treatments targeting other forms or phases of disease.
A: Is a prodrug. Sulfasalazine is indeed a prodrug, but this fact does not directly address its clinical use in ulcerative colitis maintenance, focusing instead on its chemical activation process in the gut.
C: Is effective in small bowel Crohn's disease. Sulfasalazine has limited efficacy in small bowel Crohn's disease due to poor drug delivery and absorption in that region, making it a suboptimal choice for this condition.
D: Should be avoided in glucose 6-phosphate dehydrogenase (G6PD) deficiency. While caution is advised with sulfasalazine in G6PD deficiency, this is a safety consideration rather than a primary indication or therapeutic use, thus less relevant here.
Which of the following is released in traumatized tissue, causes pain and edema, and is inactivated by angiotensin converting enzyme?
Rationale:
Bradykinin is released in traumatized tissue, causes pain and edema, and is inactivated by angiotensin converting enzyme. Bradykinin acts as a potent vasodilator increasing vascular permeability, leading to edema and pain signaling in injured areas. Its degradation by angiotensin converting enzyme regulates its levels, preventing excessive inflammation and swelling following tissue trauma.
A: Angiotensin I is a precursor molecule converted into angiotensin II, not directly causing pain or edema, nor is it released in injured tissue specifically, making it unrelated to the question’s criteria.
B: Angiotensin II primarily causes vasoconstriction and elevates blood pressure, lacking direct involvement in pain or edema in traumatized tissue, and is not the substrate inactivated by angiotensin converting enzyme here.
C: Atrial natriuretic peptide regulates blood volume and pressure through natriuresis, without causing pain or edema, and it is not known to be inactivated by angiotensin converting enzyme in damaged tissue contexts.
For each effect, select the agent that is most likely associated with it: Use with milk and an alkaline substance can cause milk-alkali syndrome
Rationale:
Use of calcium carbonate with milk and an alkaline substance can cause milk-alkali syndrome. This syndrome arises from excessive calcium intake combined with absorbable alkali, leading to hypercalcemia, metabolic alkalosis, and renal impairment. Calcium carbonate, commonly taken as an antacid or supplement, provides both calcium and alkalinity, directly contributing to this condition through increased calcium absorption and alkali load.
A: Sodium bicarbonate primarily acts as an alkaline agent without contributing significant calcium. It lacks the calcium component necessary to precipitate milk-alkali syndrome, making it less likely to cause this condition despite its alkalinity.
B: Aluminum hydroxide is an antacid that does not supply calcium. Its aluminum content does not contribute to hypercalcemia or milk-alkali syndrome, distinguishing it from calcium-containing agents responsible for this effect.
D: Magnesium hydroxide provides magnesium ions and alkalinity but no calcium. Its lack of calcium prevents it from inducing milk-alkali syndrome, which requires excess calcium intake combined with alkali.
Gynaecomastia can occur as a side effect of
Rationale:
Gynaecomastia can occur as a side effect of Cimetidine. Cimetidine, an H2 receptor antagonist, interferes with androgen receptor binding and increases estrogen activity, leading to breast tissue enlargement in males. Its anti-androgenic effects are well-documented and distinct from other H2 blockers, making it a recognized cause of gynaecomastia, especially with long-term or high-dose use.
A: Bromocriptine primarily acts as a dopamine agonist used to inhibit prolactin secretion, which typically reduces rather than causes breast tissue enlargement, making it unrelated to gynaecomastia development.
B: Levodopa, a dopamine precursor, mainly treats Parkinson’s disease and does not have known anti-androgenic or estrogenic side effects that would promote gynaecomastia.
C: Famotidine, another H2 receptor antagonist, lacks significant anti-androgenic properties or hormonal interference, which explains its negligible association with gynaecomastia compared to cimetidine.
The most efficacious drug for inhibiting round the clock gastric acid output is
Rationale:
Omeprazole is the most efficacious drug for inhibiting round the clock gastric acid output. Omeprazole, a proton pump inhibitor, irreversibly blocks the H+/K+ ATPase enzyme in gastric parietal cells, providing profound and sustained acid suppression throughout the day and night, unlike other drugs that only partially inhibit acid secretion or act for shorter durations.
B: Cimetidine blocks H2 receptors to reduce acid, but its effect is less potent and shorter-lived compared to proton pump inhibitors like omeprazole, making it less effective for continuous acid suppression.
C: Pirenzepine selectively antagonizes muscarinic receptors, reducing acid secretion moderately, but it does not provide the strong, sustained inhibition necessary for round the clock acid control.
D: Misoprostol is a prostaglandin analog that protects the gastric lining and reduces acid indirectly but does not significantly inhibit acid secretion compared to proton pump inhibitors like omeprazole.
Select the purgative that should not be taken at bed time.
Rationale:
Magnesium sulfate should not be taken at bedtime. Magnesium sulfate acts rapidly and can cause sudden bowel movements, which may disrupt sleep and lead to discomfort during the night. Bedtime ingestion risks nocturnal urgency and inconvenience, making it unsuitable for evening use compared to other gentler or slower-acting purgatives that do not provoke immediate effects.
A: Ispaghula is a bulk-forming laxative that works slowly by increasing stool volume and water content, making it safe for bedtime use without causing sudden bowel movements or nighttime disturbances.
B: Bisacodyl is a stimulant laxative, but it is often recommended for use before bedtime due to its delayed action, allowing bowel movements to occur the next morning, minimizing sleep interruption.
C: Senna stimulates bowel motility gradually and typically induces bowel movements after several hours, which generally occurs safely in the morning, reducing the likelihood of nighttime bowel urgency or disruption.
Omeprazole is most useful in
Rationale:
Omeprazole is most useful in duodenal ulcer.
Omeprazole, a proton pump inhibitor, effectively reduces gastric acid secretion, promoting healing of duodenal ulcers caused by excess acid or Helicobacter pylori infection. Its strong acid suppression creates an optimal environment for mucosal repair, making it particularly effective in managing duodenal ulcers compared to other gastrointestinal conditions requiring different treatments or less acid inhibition.
A: Gastric ulcer Omeprazole benefits gastric ulcers but is predominantly indicated for duodenal ulcers due to their higher acid-related pathology and healing response to acid suppression therapy.
C: Reflux esophagitis While omeprazole reduces acid reflux, other treatments like lifestyle changes or antacids may be necessary; it is not primarily indicated for esophagitis alone.
D: Gastritis Gastritis often involves inflammation from multiple causes; omeprazole helps acid-related cases but is less targeted or effective compared to its role in ulcer healing.
Which of the following is a decapeptide precursor of a vasoconstrictor substance?
Rationale:
Angiotensin I is a decapeptide precursor of a vasoconstrictor substance. Angiotensin I itself is inactive and consists of ten amino acids. It is converted by angiotensin-converting enzyme (ACE) into angiotensin II, which is the active vasoconstrictor. This decapeptide nature defines angiotensin I as the direct precursor involved in the renin-angiotensin system regulating blood pressure.
B: Angiotensin II is an octapeptide, not a decapeptide, and represents the active vasoconstrictor, not its precursor.
C: Atrial natriuretic peptide is a vasodilator peptide, opposing vasoconstriction, and does not serve as a decapeptide precursor.
D: Bradykinin is a nonapeptide that acts as a vasodilator, thus it cannot be a decapeptide precursor of a vasoconstrictor.
Your cousin is planning a three-week trip overseas and asks your advice regarding medications for traveler's diarrhea. A drug suitable for noninfectious diarrhea is
Rationale:
Magnesium hydroxide is suitable for noninfectious diarrhea because it acts as an osmotic laxative that can regulate bowel movements without targeting infections. It helps maintain intestinal balance and relieve symptoms by drawing water into the intestines, softening stool, and easing discomfort, making it appropriate for noninfectious cases rather than treating infectious diarrhea specifically.
A: Aluminum hydroxide primarily serves as an antacid to neutralize stomach acid rather than addressing diarrhea symptoms, limiting its effectiveness for noninfectious diarrhea management in travelers.
B: Diphenoxylate is an opioid derivative that slows bowel motility and is more appropriate for infectious diarrhea but may cause adverse effects unsuitable for general use.
D: Metoclopramide functions mainly as an antiemetic and prokinetic agent affecting gastric motility, not as a treatment for diarrhea, thus irrelevant for managing noninfectious diarrhea.
Dietary supplementation with DHEA is best documented to have therapeutic value in the treatment of
Rationale:
Dietary supplementation with DHEA is best documented to have therapeutic value in the treatment of postmenopausal osteoporosis.
DHEA supplementation has shown promise in improving bone mineral density and reducing fracture risk in postmenopausal women by influencing estrogenic activity and bone metabolism. Clinical studies support its use for skeletal health, making it a valuable adjunct in managing osteoporosis after menopause when natural hormone levels decline significantly.
A: Acne DHEA’s hormonal effects do not primarily target sebaceous gland activity or inflammatory pathways responsible for acne development, making it an unsuitable therapeutic option for acne management.
B: Diabetes insipidus This condition involves antidiuretic hormone deficiency or renal resistance, unrelated to DHEA’s hormonal functions, which do not influence water balance or urine concentration mechanisms.
C: Hirsutism in female patient Hirsutism results from androgen excess, but DHEA supplementation increases androgen precursors, potentially worsening symptoms rather than providing therapeutic benefit in this condition.
All of the following statements about stool softeners are true except
Rationale:
Stool softeners can be taken with little or no water is not true. Stool softeners require adequate fluid intake to effectively soften stool and prevent constipation complications.
A: There is minimal systemic absorption correctly describes stool softeners as they primarily act locally in the intestines, minimizing systemic side effects and making them safer for various patient populations.
B: The onset of action is usually 1-2 days accurately reflects the delayed effect typical of stool softeners, distinguishing them from stimulant laxatives that act more rapidly.
C: They are useful in patients with constipation who have experienced an acute myocardial infarction is valid because stool softeners reduce straining, lowering cardiac stress and supporting safer bowel movements post-infarction.
A gastric ulcer patient requires close follow-up to document complete ulcer healing because
Rationale:
Complete ulcer healing must be documented because there is the risk of the ulcer being cancerous. Confirming healing ensures malignancy is excluded, preventing missed diagnosis of gastric cancer, which can mimic benign ulcers. Persistent ulcers require biopsy and surveillance to distinguish benign from malignant lesions, guiding appropriate treatment and improving patient outcomes through timely intervention and monitoring.
A: Perforation into the intestine is common Perforation typically occurs into the peritoneal cavity, not the intestine, and is a less frequent complication, making this reason inadequate for requiring close follow-up.
B: Spontaneous healing of the ulcer may occur in 30%-50% of cases While spontaneous healing occurs, follow-up is necessary to confirm complete resolution and exclude malignancy, not merely because ulcers might heal without intervention.
D: Symptoms tend to be chronic and recur Symptom recurrence alone does not mandate follow-up to document healing, as symptom severity does not reliably indicate ulcer status or cancer risk.
The following stimulate gastric acid secretion:
Rationale:
Histamine stimulation of the H₂ receptor promotes gastric acid secretion. Histamine binds to H₂ receptors on parietal cells, activating adenylate cyclase and increasing cAMP, which enhances proton pump activity and acid release. This pathway is a primary mechanism driving acid secretion, making histamine a crucial stimulant, as opposed to other mediators that act differently or less directly on acid production.
A: Vagal stimulation influences acid secretion indirectly by releasing acetylcholine, but it primarily acts through muscarinic receptors, not directly through histamine pathways, making it less central in histamine-mediated acid secretion.
B: Gastrin stimulates acid secretion mainly by promoting histamine release from enterochromaffin-like cells, but it does not directly bind to H₂ receptors, distinguishing its role from histamine’s direct receptor interaction.
C: Acetylcholine stimulation of the M₁ receptor affects gastric acid secretion indirectly through neural pathways and histamine release, rather than directly activating the acid-secreting parietal cells via H₂ receptors.
Problems associated with proton pump inhibitors include:
Rationale:
Proton pump inhibitors can mask symptoms of gastric cancer. This occurs because their acid-suppressing effect alleviates gastric discomfort, potentially delaying diagnosis of underlying malignancies. Consequently, patients may experience symptom relief despite the progression of cancer, complicating timely detection and treatment. This masking effect is a significant clinical concern linked to prolonged PPI use in gastric pathology evaluation.
B: Diarrhoea, nausea, and vomiting are common side effects but are less significant compared to the serious risk of symptom masking in gastric cancer associated with PPIs. These symptoms are more general and not unique to PPIs.
C: Increased risk of gastrointestinal infection is a known consequence of acid suppression, yet it does not specifically address the critical problem of gastric cancer symptom masking, which poses a more direct diagnostic challenge.
D: Headache is a less frequently reported adverse effect and lacks direct clinical relevance to the serious complications associated with PPIs, such as obscuring serious gastric disease symptoms.
Adverse effects associated with sulfasalazine include:
Rationale:
Adverse effects associated with sulfasalazine include blood dyscrasias. Sulfasalazine can cause hematologic toxicity, including agranulocytosis, aplastic anemia, and other blood dyscrasias, due to its immunosuppressive and marrow-suppressing properties, making monitoring of blood counts essential during therapy to detect these serious complications early and adjust treatment accordingly.
B: Oligospermia Oligospermia is not commonly linked to sulfasalazine; it primarily affects male fertility by reducing sperm count, but this side effect is more frequently associated with medications like sulfasalazine’s structural analog, sulfonamides, rather than sulfasalazine itself.
C: Stevens-Johnson syndrome Stevens-Johnson syndrome is a severe skin reaction rarely reported with sulfasalazine; however, its incidence is much lower compared to other sulfa drugs, making it an unlikely common adverse effect for sulfasalazine users.
D: Systemic lupus erythematosus (SLE)-like syndrome SLE-like syndrome is not typically induced by sulfasalazine; this autoimmune condition is more characteristically triggered by drugs like hydralazine or procainamide, rather than sulfasalazine’s known adverse effect profile.
Rimonabant:
Rationale:
Rimonabant is contraindicated in, and may cause, depression. This is because it acts as a cannabinoid receptor antagonist, influencing mood regulation pathways in the brain. Clinical trials have reported increased incidence of depressive symptoms and suicidal ideation, leading to its withdrawal in many markets. Hence, its psychiatric risks make depression a significant concern for its use.
A: Inhibits insulin secretion does not align with rimonabant’s pharmacological profile, as it primarily targets cannabinoid receptors, affecting appetite and mood rather than directly impacting pancreatic insulin release.
B: Systemic absorption is minimal contradicts the drug’s known bioavailability, as rimonabant is well absorbed and distributed systemically, enabling central nervous system effects.
C: Has been associated with pulmonary hypertension lacks evidence; rimonabant’s adverse events focus on psychiatric issues rather than vascular or pulmonary complications.
Drugs useful in maintenance treatment to prevent ulcer relapse include:
Rationale:
Maintenance treatment to prevent ulcer relapse includes ranitidine.
Ranitidine is a histamine H2-receptor antagonist that reduces gastric acid secretion, promoting ulcer healing and preventing recurrence. It is effective for long-term management by maintaining a less acidic environment, which supports mucosal recovery and decreases the risk of ulcer relapse, making it the preferred agent in maintenance therapy compared to other options.
A: Aspirin increases gastric mucosal irritation and acid production, exacerbating ulcers rather than preventing relapse, making it unsuitable for maintenance therapy.
C: Sodium bicarbonate neutralizes stomach acid temporarily but lacks prolonged effects needed for ulcer healing and relapse prevention, limiting its role to symptomatic relief only.
D: Metronidazole targets Helicobacter pylori infection but is primarily used for eradication, not for ongoing maintenance to prevent ulcer recurrence after healing.
Irritant purgatives act by which of the following:
Rationale:
Irritant purgatives act by increased peristaltic activity. Irritant purgatives stimulate the intestinal mucosa, causing enhanced muscular contractions that accelerate bowel movements. This increased peristalsis helps propel fecal matter through the colon more quickly, facilitating evacuation. This mechanism contrasts with other laxative types that work via different physiological pathways, highlighting the direct stimulatory effect on intestinal motility characteristic of irritant purgatives.
A: Decreasing peristaltic activity contradicts the stimulant nature of irritant purgatives, which enhance rather than reduce intestinal muscle contractions to promote bowel movements.
C: Decreased fecal surface tension relates to surfactant laxatives, not irritant purgatives, which primarily stimulate motility rather than altering fecal consistency.
D: Bulk-forming laxatives increase stool volume by absorbing water, differing fundamentally from irritant purgatives that directly stimulate intestinal muscle contraction.
Diarrhea in children is best managed by:
Rationale:
Diarrhea in children is best managed by correction of fluid and electrolytes disturbance. Proper management focuses on restoring hydration and electrolyte balance, which prevents complications like dehydration and shock. This approach addresses the primary danger in pediatric diarrhea rather than just symptoms, ensuring the child’s safety and recovery. Supportive care is the cornerstone of treatment in pediatric diarrhea cases.
A: Anticholinergic drug Anticholinergic agents reduce intestinal motility but may cause harmful side effects in children, such as toxicity and worsening of symptoms, making them unsuitable for diarrhea management.
B: Loperamide Loperamide slows bowel movements but is contraindicated in young children due to risks of toxicity, ileus, and masking serious infections, thus not recommended for pediatric diarrhea treatment.
C: Pectin and kaolin These substances act as adsorbents but have limited efficacy and do not address dehydration or electrolyte loss, which are critical in managing diarrhea in children.
A 35-years old female patient is being treated with a number of prescription drugs, one of which is misoprostol. Which of the following is the most likely purpose for which this drug is being administered?
Rationale:
Misoprostol is most likely administered for prophylaxis of GI ulcers during long-term therapy with some non-steroidal antiinflammatory drugs. This drug acts as a prostaglandin analog, protecting the gastric mucosa by reducing acid secretion and enhancing mucus and bicarbonate production, thereby preventing NSAID-induced gastric ulcer formation in patients requiring prolonged NSAID use.
A: Routine management of gastro-esophageal reflux disease (GERD) does not commonly involve misoprostol, as proton pump inhibitors or H2 blockers are preferred treatments for acid reflux symptoms.
C: Eradicating Helicobacter pylori requires antibiotic regimens combined with acid suppression; misoprostol lacks antimicrobial properties essential for H. pylori treatment.
D: Prevention of acute stress ulcers typically uses acid-suppressing agents like proton pump inhibitors, not misoprostol, which is primarily focused on NSAID-related ulcer prevention.
A patient is receiving emetogenic chemotherapy for metastatic carcinoma. To prevent chemotherapy-induced nausea and vomiting, she is likely to be treated with
Rationale:
Dexamethasone is used to prevent chemotherapy-induced nausea and vomiting because of its antiemetic and anti-inflammatory properties. It enhances the efficacy of other antiemetics, particularly in highly emetogenic regimens, by modulating neurotransmitter release and reducing inflammation in the central nervous system, making it a standard component in antiemetic protocols for chemotherapy patients.
A: Levodopa is primarily a treatment for Parkinson’s disease by replenishing dopamine; it lacks antiemetic properties and does not prevent chemotherapy-induced nausea or vomiting.
B: Methotrexate acts as a folate antagonist used in cancer and autoimmune diseases, but it does not possess antiemetic effects and cannot prevent chemotherapy-induced nausea.
C: Misoprostol is a prostaglandin analog that protects gastric mucosa, primarily preventing NSAID-induced ulcers, and has no role in controlling chemotherapy-related nausea and vomiting.
The fastest symptomatic relief as well as highest healing rates in reflux esophagitis have been obtained with
Rationale:
Omeprazole provides the fastest symptomatic relief and highest healing rates in reflux esophagitis. It is a proton pump inhibitor that effectively suppresses gastric acid secretion, promoting mucosal healing and symptom resolution more efficiently than other treatments. Its potent acid suppression directly targets the pathophysiology of reflux, leading to superior clinical outcomes and faster recovery in patients.
A: Cisapride enhances gastrointestinal motility but does not directly reduce acid production or promote mucosal healing, making it less effective for rapid symptomatic relief and healing in reflux esophagitis.
B: Ranitidine, a histamine-2 receptor antagonist, reduces acid secretion but is less potent and slower in healing esophageal mucosa compared to proton pump inhibitors like omeprazole.
D: Sodium alginate forms a physical barrier to reduce reflux symptoms but lacks significant acid suppression or healing properties, resulting in less effective treatment for esophagitis.
A case of acute diarrhea presents with abdominal pain, fever, mucus and blood in stools and is suspected to be suffering from Shigella enteritis. What antimicrobial treatment would be most appropriate.
Rationale:
Norfloxacin is the most appropriate antimicrobial treatment for Shigella enteritis presenting with acute diarrhea, abdominal pain, fever, and bloody mucus stools. This fluoroquinolone effectively targets Shigella species by inhibiting bacterial DNA gyrase, thereby reducing disease severity and duration. It is preferred in cases requiring antibiotics due to its high efficacy against gram-negative enteric pathogens, including resistant strains of Shigella.
A: No antimicrobial treatment Neglecting antibiotics in Shigella enteritis can prolong illness and increase complications, as the infection often requires targeted therapy to eradicate invasive bacteria causing severe symptoms and prevent transmission.
B: Metronidazole Primarily effective against anaerobic bacteria and protozoa, metronidazole has limited or no activity against Shigella, a facultative anaerobic gram-negative bacillus, making it unsuitable for treating this infection.
D: Chloramphenicol Though historically used, chloramphenicol is less favored due to significant toxicity risks and widespread resistance among Shigella strains, limiting its safety and effectiveness in managing acute enteritis cases.